← Eichor
Study identifier: NCT07276529 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Initial Safety of SFM Plus OTOLoc for Creating Side-to-side or End-to-side Colorectal Anastomoses

Condition: Colorectal Cancer · Diverticular Diseases  ·  Sponsor: GI Windows, Inc.

PhaseNA
Planned participants30
Who can joinAll sexes, 22 Years to no upper limit
Healthy volunteersNo

About this study

The primary objective of this trial is to investigate the safety and effectiveness of the Flexagon 25mm SFM system plus OTOLoc when used to create a side-to-side Ileo-colic, Colo-colonic and side-to-side or end-to-side colorectal anastomoses in participants undergoing colon surgery. This will be evaluated via a composite safety/effectiveness endpoint of patient success defined as successful creation of the target anastomosis without placement procedure, device or target anastomosis related reoperation through 30 days.

This description comes directly from the study's public registry record.

Talk to the study team

Peter J Lukin, BS  ·  9787610183  ·  peter.lukin@giwindows.com

Jessica Musiak, BS  ·  617-501-7697  ·  jessica.musiak@giwindows.com

Always discuss trial participation with your own doctor first.

Locations (2)

Orlando HealthOrlando, Florida, United StatesRecruiting
University of Texas Health Science CenterHouston, Texas, United StatesNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07276529